Trodelvy benefits people with advanced hormone-positive metastatic breast cancer

https://www.facingourrisk.org/XRAY/Trodelvy-TROPICS2-mBC

Full article: https://ascopubs.org/doi/10.1200/JCO.22.01002?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

The study TROPiCS-2 showed that the drug Trodelvy (sacituzumab govitecan) improved progression-free survival when compared to chemotherapy in people with advanced metastatic ER/PR-positive, HER2-negative breast cancer who have few other treatment options. This drug does not yet have FDA approval for use in the hormone-positive setting. (Posted 1/18/23)

Update: On 02/03/2023 the FDA approved Trodelvy for patients with locally advanced or metastatic breast cancer who have received hormonal therapy and at least two other types of treatment in the metastatic setting.

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Is Trodelvy a treatment option for my type of breast cancer?
If Trodelvy is not an option for me now, might it be an option in the future?
What side effects might I experience with this treatment?
If I have serious side effects, will I need to stop treatment?
Are any other agents available to treat my cancer?

Open Clinical Trials

You can search for clinical trials for people with HR-positive or ER-positive metastatic breast cancer here.

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.